Oncocyte Corp OCX
We take great care to ensure that the data presented and summarized in this overview for Oncocyte Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OCX
View all-
Awm Investment Company, Inc. New York, NY754KShares$2.23 Million0.33% of portfolio
-
Act Capital Management, LLC Wayne, PA330KShares$973,5000.33% of portfolio
-
Defender Capital, Llc.55.9KShares$164,8600.06% of portfolio
-
American Portfolios Advisors Holbrook, NY21.8KShares$64,3980.0% of portfolio
Latest Institutional Activity in OCX
Top Purchases
Top Sells
About OCX
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Insider Transactions at OCX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 11
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 11
2024
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,420,000
+32.93%
|
$4,840,000
$2.92 P/Share
|
|
Apr 11
2024
|
Andrew Arno Director |
BUY
Open market or private purchase
|
Direct |
33,898
+32.93%
|
$67,796
$2.95 P/Share
|
|
Apr 11
2024
|
Josh Riggs CEO and President |
BUY
Open market or private purchase
|
Direct |
3,390
+49.17%
|
$6,780
$2.95 P/Share
|
|
Jun 30
2023
|
John Peter Gutfreund |
SELL
Other acquisition or disposition
|
Indirect |
3,085,047
-100.0%
|
-
|
|
Jun 23
2023
|
Lou Silverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+44.43%
|
-
|
|
Jun 23
2023
|
Alfred D Kingsley Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.93%
|
-
|
|
Jun 23
2023
|
Andrew J. Last Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+18.15%
|
-
|
|
Jun 23
2023
|
Andrew Arno Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+4.09%
|
-
|
|
Jun 14
2023
|
Alfred D Kingsley Director |
BUY
Open market or private purchase
|
Direct |
30,000
+6.01%
|
$0
$0.21 P/Share
|
|
Apr 05
2023
|
Pura Vida Investments, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
663,000
+7.57%
|
$0
$0.3 P/Share
|
|
Apr 03
2023
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Apr 03
2023
|
Broadwood Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
26,827,638
+34.84%
|
$0
$0.3 P/Share
|
|
Apr 03
2023
|
John Peter Gutfreund |
BUY
Grant, award, or other acquisition
|
Indirect |
1,000,000
+48.19%
|
$0
$0.35 P/Share
|
|
Apr 03
2023
|
John Peter Gutfreund |
BUY
Grant, award, or other acquisition
|
Direct |
705,000
+49.65%
|
$0
$0.35 P/Share
|
|
Apr 03
2023
|
Andrew Arno Director |
BUY
Grant, award, or other acquisition
|
Indirect |
282,168
+47.48%
|
$0
$0.35 P/Share
|
|
Apr 03
2023
|
Andrew Arno Director |
BUY
Grant, award, or other acquisition
|
Direct |
141,084
+17.33%
|
$0
$0.35 P/Share
|
|
Mar 06
2023
|
Pura Vida Investments, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
3,890,111
-45.88%
|
-
|
|
Dec 23
2022
|
John Peter Gutfreund |
BUY
Open market or private purchase
|
Indirect |
75,000
+50.0%
|
$0
$0.33 P/Share
|
|
Dec 23
2022
|
Andrew Arno Director |
BUY
Open market or private purchase
|
Direct |
250,000
+31.97%
|
$0
$0.35 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 2.46M shares |
|---|
| Other acquisition or disposition | 3.09M shares |
|---|